The Research on Huanglian Jiedu Decoction against Atopic Dermatitis

Objective. Study on the pharmacodynamic basis and mechanism of Huanglian Jiedu Decoction against atopic dermatitis (AD). Methods. Based on network pharmacology, the targets of Huanglian Jiedu Decoction and AD were screened by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), SwissTargetPrediction databases, and the database of Online Mendelian Inheritance in Man (OMIM), Therapeutic Targets Database (TTD) and the Comparative Toxicogenomics Database (CTD); then, chemical composition-target-related pathway-disease target network graph of Huanglian Jiedu Decoction against AD was constructed by using STRING and Cytoscape software. In combination with in vitro experiments, the levels of IL-4, IL-6, and IL-10 in T cells were determined by ELISA; the pharmacodynamic basis and mechanism of Huanglian Jiedu Decoction against AD were preliminarily explored. Results. 81 active ingredients in Huanglian Jiedu Decoction were screened by network pharmacology, 31 of which were related to atopic dermatitis, corresponding to 12 target proteins. A total of 14 pathways were obtained by KEGG pathway analysis, and 8 were associated with atopic dermatitis. Compared with the control group, 20 and 40 mu g/ml of Huanglian Jiedu Decoction could significantly reduce the contents of IL-4, IL-6, and IL-10 in T lymphocytes of mice with atopic dermatitis (p < 0.01). Conclusion. Huanglian Jiedu Decoction can act against AD by multicomponent, multitarget, and multichannel mode of action.

Automated summary

By utilizing network pharmacology, Huanglian Jiedu Decoction was shown to act against atopic dermatitis through a multi-component, multi-target, and multi-pathway mode of action, significantly reducing the levels of IL-4, IL-6, and IL-10 in T lymphocytes of mice with atopic dermatitis.